Search Details

Word: reiterations (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...February of last year, Victoria Reiter, 63, figured she had only a few months to live. A writer and translator living in Manhattan, she was suffering from chronic myeloid leukemia, an especially deadly form of blood cancer. The only treatment available was interferon, an immune-system booster that wasn't really working and that made her violently ill. Reiter had spent most of 1999 in bed, too sick to read, to walk, to do much of anything?although she had managed to put together lists dividing her possessions between her two daughters...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

...Those are only two drugs that keep EGF from doing its job. Glivec, which reversed Reiter's and Ferber's leukemia so dramatically, is another; so is Tarceva, a drug from OSI Pharmaceuticals in Uniondale, N.Y., which is showing promise against some lung tumors as well as head and neck cancers. Neither of these compounds keeps EGF from docking with cells; instead, each worms its way inside the cells, where it intercepts growth messages percolating in from the surface. Astra Zeneca, headquartered in London, is testing a similar compound, Iressa, against some lung, stomach and prostate cancers...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

...That dream comes at a price. Staying on Glivec, for example, may end up costing patients like Victoria Reiter as much as $2,400 every month?nearly $30,000 a year?for the rest of her newly prolonged life. While the National Cancer Institute funds basic research into cancer biology, the bulk of drug development is done by for-profit pharmaceutical firms. These companies claim that it costs them between $500 million and $1 billion to bring a single new medicine to market?partly because it can take 15 years for the exhaustive testing in animals and humans required...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

...February of last year, Victoria Reiter, 63, figured she had only a few months to live. A writer and translator living in Manhattan, she was suffering from chronic myeloid leukemia, an especially deadly form of blood cancer. The only treatment available was interferon, an immune-system booster that wasn't really working and that made her violently ill. Reiter had spent most of 1999 in bed, too sick to read, to walk, to do much of anything--although she had managed to put together lists dividing her possessions between her two daughters...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

Those are only two drugs that keep EGF from doing its job. Gleevec, which reversed Reiter's and Ferber's leukemia so dramatically, is another; so is Tarceva, a drug from OSI Pharmaceuticals in Uniondale, N.Y., which is showing promise against some lung tumors as well as head and neck cancers. Neither of these compounds keeps EGF from docking with cells; instead, each worms its way inside the cells, where it intercepts growth messages percolating in from the surface. Astra Zeneca, headquartered in London, is testing a similar compound, Iressa, against some lung, stomach and prostate cancers...

Author: /time Magazine | Title: New Hope For Cancer | 5/28/2001 | See Source »

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next